Pharvaris (PHVS) Surges 7.98% on Breakthrough Trial Data – What’s Next for the Biotech Play?

Summary
• Pharvaris (PHVS) surges 7.98% to $25.97, hitting a 52-week high of $26.77
• Positive Phase 3 RAPIDe-3 trial data for deucrictibant meets primary endpoint
• HC Wainwright upgrades to 'Buy' with $60 price target; Bank of America raises target to $30

Pharvaris (PHVS) is riding a wave of optimism after topline results from its Phase 3 RAPIDe-3 trial for deucrictibant, a treatment for hereditary angioedema (HAE). The stock’s 7.98% intraday gain reflects strong investor confidence in the drug’s potential and regulatory filing plans. Analyst upgrades and media coverage have amplified momentum, though profit-taking has triggered a minor pullback.

Phase 3 Trial Success Ignites Biotech Rally
Pharvaris’ 7.98% surge is directly tied to the positive RAPIDe-3 trial results, which demonstrated deucrictibant’s efficacy in reducing HAE attack duration. The median time to symptom relief (~1.28 hours vs. placebo) strengthens its on-demand treatment profile, accelerating a 2026 regulatory filing. Analysts at HC Wainwright and Bank of America have reinforced bullish sentiment, with the former setting a $60 price target and the latter raising its target to $30. Media coverage highlighting the drug’s rapid relief potential has further fueled trading volume, pushing the stock to a 52-week high of $26.77.

Biotech Sector Volatility Amid HAE Treatment Breakthroughs
The biotech sector has seen mixed performance, with Amgen (AMGN) rising 3.54% as a sector leader. However, Pharvaris’ rally is distinct, driven by its HAE-focused pipeline rather than broader sector trends. Peers like Enanta Pharmaceuticals (ENTA) and KalVista (KALV) remain range-bound, underscoring PHVS’ unique catalyst in rare disease innovation.

Options Playbook: Leveraging Volatility in PHVS
• 200-day average: 20.72 (well below current price)
• RSI: 50.64 (neutral)
• MACD: 0.21 (bullish divergence)
• Bollinger Bands: 22.80–27.53 (price near upper band)

Pharvaris’ technicals suggest a continuation of its upward trend, with key resistance at $26.77 and support at $24.40. The stock’s 7.98% gain has compressed its 52-week range, creating a high-conviction setup for aggressive bulls. With implied volatility at 79.46% for the June 2026 $25 call (PHVS20260618C25), options traders can capitalize on short-term momentum. The contract’s 4.35% leverage ratio and 0.64 delta position it to benefit from a 5% price move (projected payoff: $1.48 per share).

Top Options Picks:
• PHVS20260618C25 (Call, $25 strike, June 18, 2026):
- IV: 79.46% (high volatility)
- LVR: 4.35% (moderate leverage)
- Delta: 0.64 (moderate sensitivity)
- Theta: -0.0184 (moderate time decay)
- Gamma: 0.0273 (moderate sensitivity to price swings)
- Turnover: 8,895 (high liquidity)
- Why it stands out: High IV and liquidity make it ideal for a bullish breakout.

• PHVS20260320C25 (Call, $25 strike, March 20, 2026):
- IV: 43.70% (moderate volatility)
- LVR: 10.24% (high leverage)
- Delta: 0.619 (moderate sensitivity)
- Theta: -0.0208 (moderate time decay)
- Gamma: 0.0755 (high sensitivity to price swings)
- Turnover: 0 (low liquidity)
- Why it stands out: High gamma and leverage amplify returns if the stock breaks above $26.77.

Action Insight: Aggressive bulls should prioritize PHVS20260618C25 for a 5% upside scenario. If $26.77 holds, consider rolling into the March 2026 $30 call for extended exposure.

Backtest Pharvaris Stock Performance
The backtest of PHVS's performance following an 8% intraday increase from 2022 to the present shows favorable short-to-medium-term gains. The 3-Day win rate is 48.38%, the 10-Day win rate is 49.24%, and the 30-Day win rate is 54.00%, indicating a higher probability of positive returns in the immediate aftermath of the surge. The maximum return during the backtest was 12.22% over 30 days, suggesting that while there is some volatility, significant gains are still achievable within a month.

Pharvaris at a Pivotal Crossroads – Act Now or Miss the Wave
Pharvaris’ 7.98% rally is a testament to its Phase 3 trial success and analyst optimism, but sustainability hinges on maintaining momentum above $26.77. The stock’s technicals and options activity suggest a high-probability continuation trade, particularly for those leveraging the June 2026 $25 call. Meanwhile, sector leader Amgen (AMGN) rising 3.54% highlights broader biotech strength, but PHVS’ rare disease focus offers a unique edge. Investors should monitor the 24.40 support level and watch for follow-through volume to confirm the breakout. Act now: Buy PHVS20260618C25 if $26.77 holds, or short-term traders can scalp the 24.40–26.77 range with tight stops.